Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC

Cetuximab is a widely used drug for treating head and neck squamous cell carcinomas (HNSCCs); however, it provides restricted clinical benefits, and its response duration is limited by drug resistance. Here, we conducted randomized “Phase II-like clinical trials” of 49 HNSCC PDX models and reveal mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Yanli, Wang, Yujue, Chen, Lan, Tian, Zhen, Yang, Guizhu, Wang, Rui, Wang, Chong, Wu, Qi, Wu, Yaping, Gao, Jiamin, Kang, Xindan, Duan, Shengzhong, Zhang, Zhiyuan, Sun, Shuyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904860/
https://www.ncbi.nlm.nih.gov/pubmed/35260570
http://dx.doi.org/10.1038/s41392-022-00908-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904860/
https://www.ncbi.nlm.nih.gov/pubmed/35260570
http://dx.doi.org/10.1038/s41392-022-00908-0

Ejemplares similares